Lurbinectedin is a medication used to treat patients with small cell lung cancer (SCLC) that has progressed despite previous treatments. While Lurbinectedin has shown promising results in clinical trials, it can also cause side effects that vary in severity. According to the Mayo Clinic [2], some of the most common side effects of Lurbinectedin include fatigue, nausea, vomiting, constipation, decreased appetite, and diarrhea. Other side effects may include anemia, low white blood cell count, low platelet count, and increased risk of infections.

The long-term effects of Lurbinectedin are not yet known, as the medication has not been on the market for a long time. However, the drug's manufacturer, PharmaMar, is currently conducting long-term studies to evaluate the drug's safety and efficacy over time [1]. It is important to note that every patient's experience with Lurbinectedin may be different, and some may experience more severe side effects than others.

In conclusion, Lurbinectedin is a medication used to treat small cell lung cancer, and while it has shown promising results in clinical trials, it can cause side effects that vary in severity. The long-term effects of the medication are not yet known, but studies are currently being conducted to evaluate its safety and efficacy over time. Patients who are prescribed Lurbinectedin should speak with their healthcare provider about any concerns they may have about the medication's side effects.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804
[3] https://www.zepzelca.com/zepzelca-side-effects/